Trial Profile

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 15 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1390 (Primary) ; Dianhydrogalactitol (Primary) ; ERAS-801 (Primary) ; Paxalisib (Primary) ; Pegargiminase (Primary) ; Regorafenib (Primary) ; Troriluzole (Primary) ; VT-1021 (Primary) ; Lomustine; Temozolomide
Indications Glioblastoma; Gliosarcoma
Focus Registrational; Therapeutic Use
Acronyms GBM AGILE

31 Jul 2025 Planned number of patients changed from 1030 to 1280.
31 Jul 2025 Planned End Date changed from 1 Jun 2028 to 1 Jun 2030.
31 Jul 2025 Planned primary completion date changed from 1 Jun 2026 to 1 Jun 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com